(Q24243823)

PubMed

30 October 2023

Stephen Lawrie

3

S M

Lawrie

1 reference

PubMed

30 October 2023

Claire B Irving

1

0 references

C B Joy

author given names

C B

author last names

Joy

series ordinal

1

1 reference

PubMed

17054159

Cochrane Database of Systematic Reviews

30 October 2023

language of work or name

English

0 references

publication date

18 October 2006

0 references

published in

0 references

issue

4

0 references

cites work

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Haloperidol: a controlled trial in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

The effect of R-1625 (Haloperidol) in mental syndromes: a multiblind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Metoclopramide and Haloperidol in Tardive Dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Striatal metabolic rate and clinical response to neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Use of Haloperidol in a “Hard-Core” Chronic Schizophrenic Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Neuroleptic-potentiating effect of ?-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Extrapyramidal symptoms in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

HALOPERIDOL: A CONTROLLED CLINICAL TRIAL IN CHRONIC DISTURBED PSYCHOTIC PATIENTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Tranquilizers or Anti-Depressants for Chronic Schizophrenics: A Long Term Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Positive and negative symptoms: is their change related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Weight and blood pressure change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Phenytoin: an anti-bipolar anticonvulsant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Evidence for onset of antipsychotic effects within the first 24 hours of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Measuring quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

Haloperidol blood levels and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Depot bromperidol decanoate for schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Viloxazine and the depressed schizophrenic--methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

The new antipsychotics, and their potential for early intervention in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

1 reference

7 January 2021

Risperidone: clinical development: north American results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

The dopamine hypothesis of schizophrenia: current status, future prospects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Consistency and similarity of drug-EEG responses in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003082.PUB2

7 January 2021

10.1002/14651858.CD003082.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_oxe5fzg6wvfrfossg4awr55m74

0 references